文献速递急性肾损伤慢性肾脏病

常规临床实践中基于肌酐与胱抑素C估算的GFR不一致与不良临床结局的关系

Discordances Between Creatinine- and Cystatin C-Based Estimated GFR and Adverse Clinical Outcomes in Routine Clinical Practice.
PubMed 文献 · Am J Kidney Dis · 2023-06-23

该观察性研究纳入瑞典斯德哥尔摩2010至2018年间同日检测肌酐和胱抑素C的158,601名成人,评估基于胱抑素C的eGFR(eGFRcys)与基于肌酐的eGFR(eGFRcr)的百分比差值(eGFRdiff)与肾衰竭替代治疗、急性肾损伤、动脉粥样硬化性心血管疾病、心力衰竭及死亡的关系。结果显示eGFRcys低于eGFRcr(负eGFRdiff)者占65%,最低四分位组(eGFRcys较eGFRcr低超过27%)上述所有结局的风险均更高。

要点

  • 同日检测肌酐和胱抑素C的成人中,65%表现为eGFRcys低于eGFRcr。
  • eGFRcys较eGFRcr低超过27%者,急性肾损伤HR 2.6、肾衰竭替代治疗HR 1.4、动脉粥样硬化性心血管疾病HR 1.4、心力衰竭HR 2.0、全因死亡HR 2.6。
  • eGFRdiff为正的最高四分位组患者不良结局风险较低。

核心结论

  • 常规胱抑素C检测显示许多患者eGFRcys低于eGFRcr,这些患者多种不良结局风险更高。

研究设计与样本

  • 观察性研究,纳入2010至2018年瑞典斯德哥尔摩因医疗就诊同日检测肌酐和胱抑素C的158,601名成人(48%为女性,平均年龄62岁,eGFRcr 80 mL/min/1.73m2,eGFRcys 73 mL/min/1.73m2)。

主要发现

  • eGFRcys低于eGFRcr(负eGFRdiff)者占65%,负eGFRdiff较大者年龄更大、女性更多、eGFRcr和蛋白尿更高、合并症更多。
  • 与eGFRcys和eGFRcr相近者相比,最低四分位组(eGFRcys较eGFRcr低超过27%)急性肾损伤HR 2.6(95% CI 2.4-2.9)。
  • 最低四分位组肾衰竭替代治疗HR 1.4(95% CI 1.2-1.6),动脉粥样硬化性心血管疾病HR 1.4(95% CI 1.3-1.5)。
  • 最低四分位组心力衰竭HR 2.0(95% CI 1.9-2.2),全因死亡HR 2.6(95% CI 2.5-2.7)。
  • eGFRdiff为正的最高四分位组患者不良结局风险较低。

关键数值与推荐

  • eGFRdiff定义为eGFRcys减eGFRcr的百分比差值。
  • 最低四分位组为eGFRcys较eGFRcr低超过27%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 观察性研究。
  • 缺乏胱抑素C检测指征的信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Cystatin C is recommended for measuring estimated glomerular filtration rate (eGFR) when estimates based on creatinine (eGFRcr) are not thought to be accurate enough for clinical decision making. While global adoption is slow, routine cystatin C testing in Sweden has been available for over a decade, providing real-world evidence about the magnitude of differences between eGFRcys and eGFRcr and their association with clinical outcomes. STUDY DESIGN: Observational study. SETTING & PARTICIPANTS: 158,601 adults (48% women; mean age 62 years, eGFRcr 80, and eGFRcys 73mL/min/1.73/m2) undergoing testing for creatinine and cystatin C on the same day in connection with a health care encounter during 2010-2018 in Stockholm, Sweden. EXPOSURE: Percentage difference of eGFRcys minus eGFRcr (eGFRdiff). OUTCOME: Kidney failure with replacement therapy (KFRT), acute kidney injury (AKI), atherosclerotic cardiovascular disease (ASCVD), heart failure, and death. ANALYTICAL APPROACH: Multivariable Cox proportional hazards regression. RESULTS: Discordances between eGFRcr and eGFRcys were common, with eGFRcys being lower than eGFRcr (negative eGFRdiff) in most cases (65%). Patients with larger negative eGFRdiff were older, more often female, with higher eGFRcr and albuminuria, and more comorbid conditions. Compared with patients with similar eGFRcys and eGFRcr, the lowest quartile (eGFRcys > 27% lower than eGFRcr) had the higher HR of all study outcomes: AKI, 2.6 (95% CI, 2.4-2.9); KFRT, 1.4 (95% CI, 1.2-1.6); ASCVD, 1.4 (95% CI, 1.3-1.5); heart failure, 2.0 (95% CI, 1.9-2.2); and all-cause death, 2.6 (95% CI, 2.5-2.7). Conversely, patients in the highest quartile (positive eGFRdiff) were at lower risk. LIMITATIONS: Observational study, lack of information on indications for cystatin C testing. CONCLUSIONS: Cystatin C testing in routine care shows that many patients have a lower eGFRcys than eGFRcr, and these patients have a higher risk of multiple adverse outcomes. PLAIN-LANGUAGE SUMMARY: Clinicians require guidance when there are discrepancies between the estimated glomerular filtration rate based on creatinine (eGFRcr) and based on cystatin C (eGFRcys) in the same individual. Routine cystatin C testing in Sweden for over a decade permits exploration of how common and large these discrepancies are, and their associations with adverse clinical outcomes. In this observational study, we found that discordances between eGFRcys and eGFRcr are common, and 1 in 4 patients tested had an eGFRcys > 28% lower than their eGFRcr. We also show that an eGFRcys that is lower than the eGFRcr consistently identifies patients at higher risk of adverse outcomes, including cardiovascular events, kidney replacement therapy, acute kidney injury, and death.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Carrero JJ, Fu EL, Sang Y, et al. Discordances Between Creatinine- and Cystatin C-Based Estimated GFR and Adverse Clinical Outcomes in Routine Clinical Practice. Am J Kidney Dis. 2023. PMID: 37354936. doi:10.1053/j.ajkd.2023.04.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。